Xiaohua Zhou
Physical Medicine & Rehabilitation · Birmingham, ALNPI 1679580146
Payments from drug & device makers
What this record shows
Ipsen Pharma SAS accounts for 72.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,227 and has fallen 97.5% since, to $31 in 2025.
Across 22 payments — averaging $77.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Pharma SAS$1K
- AbbVie$264
- Ipsen Biopharmaceuticals, Inc$119
- Avanir Pharmaceuticals, Inc.$32
- Saol Therapeutics Inc.$29
- Pacira Pharmaceuticals Incorporated$28
Across 159 payments — averaging $1380.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$219K
What the payments were for
- Travel & lodging$93855%
- Food & beverage$76245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Pharma SAS | 2 | $1,227 |
| AbbVie | 12 | $264 |
| Ipsen Biopharmaceuticals, Inc | 4 | $119 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Saol Therapeutics Inc. | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,700 in reported general payments places this provider in the 75th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 34 | $720 |
| Tizanidine Hcl | 25 | $698 |
| Baclofen | 35 | $696 |
| Methocarbamol | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Birmingham
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Matthew BerkeBirmingham$6K
- Chong WengBirmingham$4K
- Kenneth SmithBirmingham$4K
- Srinivas MallempatiBirmingham$3K
- Aaron GreenbergBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.